Literature DB >> 27108948

Renoprotective approaches and strategies in acute kidney injury.

Yuan Yang1, Meifang Song1, Yu Liu1, Hong Liu1, Lin Sun1, Youming Peng1, Fuyou Liu2, Manjeri A Venkatachalam3, Zheng Dong4.   

Abstract

Acute kidney injury (AKI) is a major renal disease associated with high mortality rate and increasing prevalence. Decades of research have suggested numerous chemical and biological agents with beneficial effects in AKI. In addition, cell therapy and molecular targeting have been explored for reducing kidney tissue damage and promoting kidney repair or recovery from AKI. Mechanistically, these approaches may mitigate oxidative stress, inflammation, cell death, and mitochondrial and other organellar damage, or activate cytoprotective mechanisms such as autophagy and pro-survival factors. However, none of these findings has been successfully translated into clinical treatment of AKI. In this review, we analyze these findings and propose experimental strategies for the identification of renoprotective agents or methods with clinical potential. Moreover, we propose the consideration of combination therapy by targeting multiple targets in AKI.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Acute kidney injury; Ischemia–reperfusion; Kidney protection; Kidney repair; Nephrotoxicity; Renoprotection

Mesh:

Substances:

Year:  2016        PMID: 27108948      PMCID: PMC5123830          DOI: 10.1016/j.pharmthera.2016.03.015

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  241 in total

1.  Effect of a recombinant manganese superoxide dismutase on prevention of contrast-induced acute kidney injury.

Authors:  Antonio Pisani; Massimo Sabbatini; Eleonora Riccio; Roberta Rossano; Michele Andreucci; Clemente Capasso; Viviana De Luca; Vincenzo Carginale; Mariano Bizzarri; Antonella Borrelli; Antonella Schiattarella; Michele Santangelo; Aldo Mancini
Journal:  Clin Exp Nephrol       Date:  2013-06-27       Impact factor: 2.801

2.  Autologous cell therapy for cisplatin-induced acute kidney injury by using non-expanded adipose tissue-derived cells.

Authors:  Kaoru Yasuda; Takenori Ozaki; Yousuke Saka; Tokunori Yamamoto; Momokazu Gotoh; Yasuhiko Ito; Yukio Yuzawa; Seiichi Matsuo; Shoichi Maruyama
Journal:  Cytotherapy       Date:  2012-06-25       Impact factor: 5.414

Review 3.  Rationale of mesenchymal stem cell therapy in kidney injury.

Authors:  Susanne V Fleig; Benjamin D Humphreys
Journal:  Nephron Clin Pract       Date:  2014-09-24

4.  Hematopoietic microRNA-126 protects against renal ischemia/reperfusion injury by promoting vascular integrity.

Authors:  Roel Bijkerk; Coen van Solingen; Hetty C de Boer; Pieter van der Pol; Meriem Khairoun; Ruben G de Bruin; Annemarie M van Oeveren-Rietdijk; Ellen Lievers; Nicole Schlagwein; Danielle J van Gijlswijk; Marko K Roeten; Zeinab Neshati; Antoine A F de Vries; Mark Rodijk; Karin Pike-Overzet; Yascha W van den Berg; Eric P van der Veer; Henri H Versteeg; Marlies E J Reinders; Frank J T Staal; Cees van Kooten; Ton J Rabelink; Anton Jan van Zonneveld
Journal:  J Am Soc Nephrol       Date:  2014-03-07       Impact factor: 10.121

5.  The RIP1-kinase inhibitor necrostatin-1 prevents osmotic nephrosis and contrast-induced AKI in mice.

Authors:  Andreas Linkermann; Jan-Ole Heller; Agnes Prókai; Joel M Weinberg; Federica De Zen; Nina Himmerkus; Attila J Szabó; Jan H Bräsen; Ulrich Kunzendorf; Stefan Krautwald
Journal:  J Am Soc Nephrol       Date:  2013-07-05       Impact factor: 10.121

6.  SIRT1 overexpression decreases cisplatin-induced acetylation of NF-κB p65 subunit and cytotoxicity in renal proximal tubule cells.

Authors:  Yu Jin Jung; Jung Eun Lee; Ae Sin Lee; Kyung Pyo Kang; Sik Lee; Sung Kwang Park; Sang Yong Lee; Myung Kwan Han; Duk Hoon Kim; Won Kim
Journal:  Biochem Biophys Res Commun       Date:  2012-02-05       Impact factor: 3.575

7.  Microvesicles derived from human adult mesenchymal stem cells protect against ischaemia-reperfusion-induced acute and chronic kidney injury.

Authors:  Stefano Gatti; Stefania Bruno; Maria Chiara Deregibus; Andrea Sordi; Vincenzo Cantaluppi; Ciro Tetta; Giovanni Camussi
Journal:  Nephrol Dial Transplant       Date:  2011-02-15       Impact factor: 5.992

8.  Accelerated recovery of renal mitochondrial and tubule homeostasis with SIRT1/PGC-1α activation following ischemia-reperfusion injury.

Authors:  Jason A Funk; Rick G Schnellmann
Journal:  Toxicol Appl Pharmacol       Date:  2013-10-03       Impact factor: 4.219

9.  Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan.

Authors:  Konrad T Howitz; Kevin J Bitterman; Haim Y Cohen; Dudley W Lamming; Siva Lavu; Jason G Wood; Robert E Zipkin; Phuong Chung; Anne Kisielewski; Li-Li Zhang; Brandy Scherer; David A Sinclair
Journal:  Nature       Date:  2003-08-24       Impact factor: 49.962

10.  The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin.

Authors:  Alexander V Birk; Shaoyi Liu; Yi Soong; William Mills; Pradeep Singh; J David Warren; Surya V Seshan; Joel D Pardee; Hazel H Szeto
Journal:  J Am Soc Nephrol       Date:  2013-07-11       Impact factor: 10.121

View more
  38 in total

1.  Nucleophosmin Phosphorylation as a Diagnostic and Therapeutic Target for Ischemic AKI.

Authors:  Zhiyong Wang; Erdjan Salih; Chinaemere Igwebuike; Ryan Mulhern; Ramon G Bonegio; Andrea Havasi; Steven C Borkan
Journal:  J Am Soc Nephrol       Date:  2019-01       Impact factor: 10.121

2.  IL233, A Novel IL-2 and IL-33 Hybrid Cytokine, Ameliorates Renal Injury.

Authors:  Marta E Stremska; Sheethal Jose; Vikram Sabapathy; Liping Huang; Amandeep Bajwa; Gilbert R Kinsey; Poonam R Sharma; Saleh Mohammad; Diane L Rosin; Mark D Okusa; Rahul Sharma
Journal:  J Am Soc Nephrol       Date:  2017-05-24       Impact factor: 10.121

Review 3.  Mitochondrial energetics in the kidney.

Authors:  Pallavi Bhargava; Rick G Schnellmann
Journal:  Nat Rev Nephrol       Date:  2017-08-14       Impact factor: 28.314

Review 4.  DNA damage response in nephrotoxic and ischemic kidney injury.

Authors:  Mingjuan Yan; Chengyuan Tang; Zhengwei Ma; Shuang Huang; Zheng Dong
Journal:  Toxicol Appl Pharmacol       Date:  2016-10-27       Impact factor: 4.219

5.  Scintigraphic evaluation of remote pre-conditioning protection against unilateral renal ischemia/reperfusion injury in rats: a longitudinal study.

Authors:  Zahra Sedaghat; Hossein Fatemikia; Kaveh Tanha; Maria Zahiri; Majid Assadi
Journal:  Int Urol Nephrol       Date:  2019-08-12       Impact factor: 2.370

6.  Stress granules are formed in renal proximal tubular cells during metabolic stress and ischemic injury for cell survival.

Authors:  Shixuan Wang; Sang-Ho Kwon; Yunchao Su; Zheng Dong
Journal:  Am J Physiol Renal Physiol       Date:  2019-05-15

7.  Systematic analysis of the expression profile of non-coding RNAs involved in ischemia/reperfusion-induced acute kidney injury in mice using RNA sequencing.

Authors:  Jun Zhou; Hongtao Chen; Youling Fan
Journal:  Oncotarget       Date:  2017-10-26

8.  Lipid imaging for visualizing cilastatin amelioration of cisplatin-induced nephrotoxicity.

Authors:  Estefanía Moreno-Gordaliza; Diego Esteban-Fernández; Alberto Lázaro; Sarah Aboulmagd; Blanca Humanes; Alberto Tejedor; Michael W Linscheid; M Milagros Gómez-Gómez
Journal:  J Lipid Res       Date:  2018-07-26       Impact factor: 5.922

9.  FOXO1 inhibition prevents renal ischemia-reperfusion injury via cAMP-response element binding protein/PPAR-γ coactivator-1α-mediated mitochondrial biogenesis.

Authors:  Di Wang; Yanqing Wang; Xiantong Zou; Yundi Shi; Qian Liu; Tianru Huyan; Jing Su; Qi Wang; Fengxue Zhang; Xuejun Li; Lu Tie
Journal:  Br J Pharmacol       Date:  2019-12-23       Impact factor: 8.739

10.  Acute kidney disease in hospitalized acute kidney injury patients.

Authors:  Ping Yan; Xiang-Jie Duan; Yu Liu; Xi Wu; Ning-Ya Zhang; Fang Yuan; Hao Tang; Qian Liu; Ying-Hao Deng; Hong-Shen Wang; Mei Wang; Shao-Bin Duan
Journal:  PeerJ       Date:  2021-05-24       Impact factor: 2.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.